Your AI-Trained Oncology Knowledge Connection!

Ovarian Cancer: Frontline Therapy : Episode 4

Front Line Maintenance Options in Advanced Ovarian Cancer

April 8, 2021

By Rebecca Previs, MD

Video

An expert oncologist reviews therapeutic options for front line maintenance in advanced ovarian cancer.

EP: 1.Initial Therapy Options for Advanced Ovarian Cancer

EP: 2.Role of Bevacizumab for Initial Therapy in Advanced Ovarian Cancer

EP: 3.Somatic and Germline Testing in Advanced Ovarian Cancer

EP: 4.Front Line Maintenance Options in Advanced Ovarian Cancer

EP: 5.Selecting a PARP Inhibitor for Front Line Maintenance in Advance Ovarian Cancer

EP: 6.Identifying Patients Appropriate for Front Line Maintenance Therapy in Advanced Ovarian Cancer

EP: 7.Impact of Initial Therapy on Front Line Maintenance Treatment Choice in Advanced Ovarian Cancer

EP: 8.Emerging Front-Line Maintenance Therapies for Advanced Ovarian Cancer

EP: 9.Treatment Considerations for PARP Inhibitors in First-Line Maintenance Therapy in Patients With Advanced Ovarian Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.

Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.

Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.